Live Free or Die Legal
This website is not an official source of law. This website does not provide legal advice. For official legal materials, verify against the relevant court, legislature, agency, or other official source. Legal information may be incomplete, outdated, or incorrectly processed. Consult a qualified attorney for advice about a specific legal matter.

This page is an unofficial mirror and is not legal advice. Verify the document against the official source before relying on it.

HB1638-FN: creating a bypass mechanism for health insurer step therapy protocols when medically necessary.

Document type
Bill
Status
HOUSE
Jurisdiction
NH
Branch
legislative
Citation
HB1638-FN
Official source linked
Yes
Unofficial mirror
Yes
Extraction status
Completed
OCR status
Unknown
Official source

Bill details

Version history, amendments, and roll-call votes were not present in the imported local bill data.

Bill number
HB1638-FN
Session year
2026
Status
HOUSE

Official links

y peer-reviewed, evidence-based literature; and III. Approved by the United States Food and Drug Administration. 420-J:34 Rules. The commissioner may adopt rules, pursuant to RSA 541-A, to assist the insurance department with the implement this section. 2 Effective Date. This act shall take effect 90 days after its passage. LBA 26-3029 12/2/25 HB 1638-FN- FISCAL NOTE AS INTRODUCED

Extraction diagnostics

Source fetched
no
Official source URL
yes
PDF mirrored
no
Text extracted
yes

Related law links

RSA references from bill data

  • 420-J · amend

    ep therapy protocols when medically necessary. Be it Enacted by the Senate and House of Representatives in General Court convened: 1 New Subdivision; Step Therapy. Amend RSA 420-J by inserting after section 26 the following new subdivision: Step Therapy 420-J:27 Definitions. As used in this subdivision: I. "Advanced, metastatic cancer" means a cancer that has spread from the primary or orig

  • 420-J:28 · add

    ce, research and newly developed treatments. 420-J:29 Absence of Clinical Practice Guidelines. In the absence of clinical practice guidelines that satisfy the requirements under RSA 420-J:28, peer-reviewed publications may be used as a substitute. 420-J:30 Consideration of Atypical Populations and Diagnoses. When establishing a step therapy protocol, a utilization review organization shall also take into

  • 541-A · reference

    y peer-reviewed, evidence-based literature; and III. Approved by the United States Food and Drug Administration. 420-J:34 Rules. The commissioner may adopt rules, pursuant to RSA 541-A, to assist the insurance department with the implement this section. 2 Effective Date. This act shall take effect 90 days after its passage. LBA 26-3029 12/2/25 HB 1638-FN- FISCAL NOTE AS INTRODUCED

RSAs mentioned by this document